“Global Neurostimulation Devices market set to grow to $13bn by 2024” says new Visiongain report

28 November 2018
Pharma
Visiongain has launched a new pharma report Global Neurostimulation Devices Market 2019-2029: Spinal Cord Stimulators, Deep Brain Stimulators, Vagus Nerve Stimulators, Sacral Nerve Stimulators, Cortical Stimulators, Epilepsy, Pain Management, Hearing Loss, Incontinence, Gastroparesis, Parkinson’s Disease Neurostimulation is an advanced treatment which helps to reduce certain types of chronic pain. Neurostimulation works by intercepting pain signals before they reach the brain. are different types of neurostimulation devices available in the market, namely spinal cord stimulators, deep brain stimulators, vagus nerve stimulators, sacral nerve stimulators, and cortical stimulators among others. The lead analyst of the report commented "The leading medical device manufacturers are focusing on entering the emerging Asia-Pacific & Latin American countries to open manufacturing facility to capture the low-cost manufacturing advantage and to cater the significantly rising demand for medical devices from these regions. Thus, rising demand for medical devices from emerging markets is expected to create significant opportunities for global neurostimulation devices market vendors and the overall market." Leading companies featured in the report include Advanced Bionics, Boston Scientific Corporation, Cochlear ltd, Cyberonics, Medtronic, Neuronetics Inc, Nervo Corp., Cogentic Medical Inc, St Jude Medicall, NDI Medical Notes for Editors If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100 About Visiongain Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors. Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Biosimilars and Follow-On Biologics Drugs market set to grow to $14bn by 2024” says new Visiongain report

Growth will be restrained in the biosimilar growth hormones submarket by steady uptake for branded therapies, high brand loyalty, as well as the launch of long-acting growth hormones.

21 March 2019

Read

“Global Asthma & COPD Therapies market set to grow to $46bn by 2024” says new Visiongain report

ecent studies and expert opinion suggest that the asthma and COPD market is more segregated than previously believed.

19 March 2019

Read

“Global Anaesthesia Drugs market set to grow to $11.8bn by 2024” says new Visiongain report

The intravenous route is the most commonly used route of administration owing to its high effectiveness during critical surgeries, its high adoption in hospitals, and availability of advanced intravenous drugs which cater the need of surgeons.

19 March 2019

Read

“The Global Pharma Contract Sales market will be driven by cost saving and the need for more flexibility” says new Visiongain report

With higher-cost therapies in development, combined with increasing burdens on healthcare budgets from ageing populations and rising disease incidence, market access is becoming more challenging in countries worldwide.

28 February 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever
WOOCS 2.2.1